RHINOMED LIMITED RNO

RNO ASX
RNO
RHINOMED LIMITED ASX
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E

RNO Chart

Trade RNO with trusted brokers on TradingView Open account
Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Health Technology
Industry: Biotechnology
Rhinomed Ltd. is medical technology company, which engages in the identification, acquisition, and commercialization of stage therapeutic delivery technologies. It operates through Turbine, Mute and Pronto technology. The Turbine technology, a nasal dilator designed to assist breathe during aerobic exercise. The Mute technology, a nasal technology that is designed to improve sleep by breathing more and snoring less. The Pronto technology is a Vapor Inhaler, which opens the nose to improve airflow and delivers the soothing vapors from essential oils. The company was founded on February 9, 2004 and is headquartered in Cremorne, Australia.